文献速递银屑病与炎症性皮肤病

银屑病患者外周血细胞信号分子磷酸化:原研与生物类似药英利昔单抗比较

Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab.
PubMed 文献 · Br J Dermatol · 2018-05-30

本研究采用流式细胞术检测25例接受英利昔单抗治疗的银屑病患者和19例健康对照者外周血单个核细胞中NF-κB、ERK1/2、p38 MAPK和STAT3的磷酸化水平。结果显示,即使临床缓解,患者磷酸化水平仍高于健康对照;继续治疗下原研药与生物类似药CT-P13均使磷酸化水平下降,12个月后两组间无显著差异。

要点

  • 银屑病患者PBMCs磷酸化水平高于健康对照,提示持续系统炎症。
  • 原研英利昔单抗与生物类似药CT-P13治疗12个月后磷酸化水平无显著差异。
  • 从原研药转换为CT-P13未影响磷酸化水平或临床参数。

核心结论

  • 接受英利昔单抗治疗的银屑病患者PBMCs活化水平高于健康对照,可能反映系统炎症。
  • 从原研英利昔单抗转换为生物类似药CT-P13未影响磷酸化水平或临床参数,提示CT-P13为非劣效治疗选择。

研究设计与样本

  • 研究纳入25例接受英利昔单抗治疗的银屑病患者和19例健康对照者。
  • 采用流式细胞术检测单核细胞及T、B、NK、CD3+CD56+细胞中NF-κB、ERK1/2、p38 MAPK和STAT3的磷酸化水平(TNF-α刺激前后)。

主要发现

  • 入组时,尽管已达临床缓解,银屑病患者PBMCs磷酸化水平仍高于健康对照。
  • 继续治疗下,原研英利昔单抗和生物类似药组患者磷酸化水平均下降。
  • 治疗12个月后,两种药物间未检测到显著差异。

临床怎么用

  • 临床可参考:银屑病患者即使临床缓解,外周血细胞信号分子磷酸化仍可能升高。
  • 从原研英利昔单抗转换为CT-P13未显示对磷酸化水平或临床参数的不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis vulgaris is a chronic, inflammatory skin disease characterized by a dysregulated immune response and it is associated with substantial systemic comorbidities. Biological drugs such as tumour necrosis factor (TNF)-α inhibitors can ameliorate the disease but are expensive. Biosimilar drugs have the same amino-acid sequence as the originator, but differences in manufacturing can affect biological activity, efficacy and tolerability. OBJECTIVES: To explore potential differences in intracellular phosphorylation of signalling molecules in peripheral blood cells from patients with psoriasis treated with the TNF-α inhibitor infliximab compared with healthy controls, and to investigate if the phosphorylation pattern was influenced by switching from the originator infliximab to the biosimilar CT-P13. METHODS: By flow cytometry, we measured phosphorylation of nuclear factor kappa B, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase and signal transducer and activator of transcription 3, before and after TNF-α stimulation in monocytes and T, B, natural killer and CD3+ CD56+ cells from 25 patients with psoriasis treated with infliximab and 19 healthy controls. RESULTS: At inclusion, phosphorylation levels of peripheral blood mononuclear cells (PBMCs) were increased in patients with psoriasis compared with healthy controls, even though clinical remission had already been achieved. Phosphorylation levels declined in patients on both originator infliximab and biosimilar during continued treatment. No significant differences were detected between the two medications after 12 months. CONCLUSIONS: Patients with psoriasis on infliximab have higher activation levels of PBMCs than do healthy controls, possibly reflecting systemic inflammation. Switching from the originator infliximab to biosimilar CT-P13 did not affect phosphorylation levels or clinical parameters, suggesting that CT-P13 is a noninferior treatment alternative to the originator infliximab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Aarebrot AK, Solberg SM, Davies R, et al. Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab. Br J Dermatol. 2018. PMID: 29274242. doi:10.1111/bjd.16269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。